1. Home
  2. SMX vs MDXH Comparison

SMX vs MDXH Comparison

Compare SMX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SMX (Security Matters) Public Limited Company

SMX

SMX (Security Matters) Public Limited Company

HOLD

Current Price

$15.65

Market Cap

19.7M

Sector

Technology

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.43

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMX
MDXH
Founded
N/A
2003
Country
Ireland
Belgium
Employees
19
N/A
Industry
Industrial Machinery/Components
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
19.7M
21.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SMX
MDXH
Price
$15.65
$0.43
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
44.7K
786.3K
Earning Date
04-23-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.40
52 Week High
$490.00
$5.33

Technical Indicators

Market Signals
Indicator
SMX
MDXH
Relative Strength Index (RSI) 57.50 29.77
Support Level $15.39 N/A
Resistance Level $17.72 $3.79
Average True Range (ATR) 1.89 0.05
MACD -0.07 0.03
Stochastic Oscillator 66.38 23.35

Price Performance

Historical Comparison
SMX
MDXH

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: